<DOC>
	<DOCNO>NCT00718718</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety subcutaneous ( skin ) administration anti-interleukin-6 monoclonal antibody ( CNTO 136 ) reduce sign symptom participant active rheumatoid arthritis ( RA ) methotrexate ( MTX ) therapy .</brief_summary>
	<brief_title>A Study Effectiveness Safety CNTO 136 Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description>This multicenter , double-blind ( neither physician participant know treatment participant receives ) , randomize ( study medication assign chance ) , placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) study . This study conduct 2 part ( Part A Part B ) . Each part consist 3 phase : screening ( approximately 1 month prior start study medication ) , treatment phase ( Part A : 22 week Part B : 24 week ) , follow-up phase ( approximately 4 month last administration study medication ) . In Part A , participant randomly assign 2 group receive CNTO 136 100 mg placebo 22 week . All participant Part A , cross Week 12 placebo CNTO 136 ( Group 1 ) CNTO 136 placebo ( Group 2 ) . In Part B , participant randomly assign 5 group receive placebo and/or 1 3 dos CNTO 136 ( 100mg , 50mg 25mg ) 24 week . Participants Part B , Group 1 cross Week 12 placebo CNTO 136 . All participant maintain stable dose MTX least 6 week prior start study medication Week 24 . Safety evaluate assessment adverse event , vital sign , clinical finding , 12-lead electrocardiogram , clinical laboratory test monitor throughout study . The total duration study participation participant approximately 42 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosed rheumatoid arthritis ( RA ) least 4 month prior screen Have treat inadequate response tolerate dose methotrexate ( MTX ) ( least 15mg/week ) least 4 month prior screen . MTX dose 10 12.5 mg/week allow participant intolerance 15 mg/week MTX route administration dose ( exceed 25 mg/week ) stable least 6 week prior start study medication Have active RA define persistent disease activity least 6 swollen 6 tender joint , time screen baseline , either anticyclic citrullinated peptide antibodypositive rheumatoid factor positive screening Creactive protein great equal 1.0 mg/dL ( 10 mg/L ) Agree use one contraception method define protocol Have inflammatory disease RA might confound evaluation benefit CNTO 136 therapy arthritis Family history of/ long QT syndrome ; history second thirddegree heart block Received systemic immunosuppressive disease modify antirheumatic drug MTX , sulfasalazine , hydroxychloroquine chloroquine within 4 week prior start study medication Received intra articular ( joint ) , intramuscular , intravenous corticosteroid within 4 week prior start study medication Positive human immunodeficiency virus test , hepatitis B hepatitis C History / chronic recurrent infectious disease , history / active tuberculosis Have serious infection within 2 month prior start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Active Rheumatoid Arthritis</keyword>
	<keyword>CNTO 136</keyword>
	<keyword>Interleukin-6</keyword>
	<keyword>Anti-interleukin-6 monoclonal antibody</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Placebo</keyword>
</DOC>